In this episode, we explore the complexities of Progressive Supranuclear Palsy (PSP), a rare neurodegenerative tauopathy defined by the pathological accumulation of four-repeat (4R) tau protein in the brain,. We examine the diverse clinical phenotypes of the disease, ranging from the classic Richardson’s syndrome—characterized by vertical supranuclear gaze palsy and early falls—to variants such as PSP-parkinsonism and progressive gait freezing, which often lead to initial misdiagnosis,,. The discussion highlights the 2017 Movement Disorder Society criteria aimed at improving diagnostic sensitivity, alongside genetic risk factors involving the MAPT H1 haplotype and loci such as MOBP and EIF2AK3,,. Finally, we cover current management strategies that rely on multidisciplinary care therapies and symptomatic relief,, while looking ahead to the promise of emerging biomarkers like neurofilament light chain (NfL) and innovative clinical initiatives like the PSP Trial Platform (PTP),,.

In this episode, we explore thyroid ectopia, a rare developmental anomaly where the thyroid gland fails to migrate to its correct anatomical position in the neck, most frequently manifesting as a lingual thyroid at the base of the tongue. We examine the genetic architectures behind this condition, highlighting the roles of critical transcription factors like FOXE1, PAX8, and NKX2-1 in thyroid morphogenesis, and discuss clinical presentations which range from asymptomatic masses to obstructive symptoms like dysphagia and dyspnoea, often accompanied by primary congenital hypothyroidism. Finally, we review diagnostic strategies involving radionuclide scintigraphy and ultrasound, alongside management protocols that balance levothyroxine suppression therapy with surgical interventions such as transoral robotic surgery (TORS) for severe cases or rare malignancies.

To put it simply, thyroid ectopia is like a commuter who gets off the train several stops too early; the gland sets up shop and attempts to work in a location it was never meant to occupy, such as the back of the throat, rather than completing its journey to the lower neck.

In this episode, we explore Dentinogenesis Imperfecta (DGI), a hereditary disorder of tooth development characterized by discolored, "opalescent" teeth that are prone to severe attrition, fracture, and premature loss due to abnormal dentin structure. We examine the genetic underpinnings of the disease, distinguishing between syndromic forms associated with Osteogenesis Imperfecta (linked to COL1A1 or COL1A2 mutations) and isolated forms caused by mutations in the ** DSPP gene**, while highlighting how classification systems have evolved from the traditional Shields classification to modern proposals that view isolated DGI types as a continuum of severity. Finally, we discuss the necessity of early, multidisciplinary management—ranging from stainless steel crowns in childhood to complex prosthodontics in adulthood—to address clinical challenges like pulp obliteration and to mitigate the significant psychosocial impact the condition has on patient quality of life.

In this episode, we explore Atopic Keratoconjunctivitis (AKC), a severe, chronic inflammatory eye disease that primarily affects adults between 20 and 50 years old with a history of atopic dermatitis or asthma. We discuss the condition's distinct clinical features—such as intense itching, eczematous eyelids, and lower tarsal conjunctival involvement—and how to differentiate it from the pediatric-onset Vernal Keratoconjunctivitis. Finally, we review management strategies ranging from topical antihistamines and corticosteroids to steroid-sparing immunomodulators like tacrolimus and cyclosporine, as well as surgical interventions for preventing permanent vision loss from corneal scarring.

In this episode, we explore the evolving landscape of Cerebral Cavernous Malformations (CCMs), covering the latest 2025 clinical care guidelines and the distinct genetic drivers behind familial and sporadic cases, including mutations in KRIT1, CCM2, PDCD10, and PIK3CA. We discuss the nuance of management strategies, ranging from conservative observation and microsurgical resection to minimally invasive Laser Interstitial Thermal Therapy (LITT) for epilepsy and deep-seated lesions. Finally, we review the current status of pharmacological research, noting the discontinuation of the REC-994 trial while highlighting promising developments in focused ultrasound and ROCK inhibitors like NRL-1049.

In this episode, we examine Lennox-Gastaut Syndrome (LGS), a severe developmental and epileptic encephalopathy characterised by a triad of drug-resistant seizures, cognitive impairment, and distinct electroencephalogram (EEG) patterns. We explore the evolving treatment landscape, which includes newer pharmacological options like fenfluramine and cannabidiol alongside surgical interventions such as corpus callosotomy and vagus nerve stimulation. Finally, we discuss the significant burden placed on caregivers and the complex challenges families face when transitioning from paediatric to adult care systems.

In this episode, we examine Young Onset Parkinson’s Disease (YOPD), a distinct clinical entity affecting individuals diagnosed between the ages of 21 and 50. We explore how YOPD differs from late-onset disease through a stronger genetic architecture—frequently involving genes such as PRKN, PINK1, and LRRK2—and a motor phenotype often characterised by early dystonia and rigidity. The discussion covers the clinical paradox of YOPD: while patients often experience slower motor progression and preserved cognition for longer periods, they face a significantly higher risk of treatment complications, specifically levodopa-induced dyskinesia. Finally, we address the unique psychosocial burdens regarding employment and family life, alongside recent epidemiological data showing rising global incidence, particularly in East Asia, and the strong association between cognitive decline and mortality in this specific population.

In this episode, we explore Hirschsprung disease, a congenital condition characterised by the absence of ganglion cells in the distal bowel, leading to functional obstruction. We discuss the complex genetic landscape involving RET and EDNRBvariants, diagnostic advances comparing calretinin immunohistochemistry with traditional acetylcholinesterase staining, and the efficacy of surgical techniques such as the Soave, Swenson, and Duhamel procedures. Finally, we examine the management of Hirschsprung-associated enterocolitis and the long-term impact on bowel function, fertility, and quality of life in adulthood.

In this episode, we explore Systemic Sclerosis (SSc), examining its defining pathogenic triad of vasculopathy, autoimmunity, and fibrosis. We discuss the 2013 ACR/EULAR classification criteria, which improved diagnosis by weighing early signs like Raynaud’s phenomenon, puffy fingers, and specific autoantibodies alongside skin thickening. The episode covers critical organ risks—specifically Interstitial Lung Disease (ILD) and Pulmonary Arterial Hypertension (PAH) as leading causes of mortality—and the role of biomarkers like anti-topoisomerase I and anti-RNA polymerase III in predicting complications such as cardiac fibrosis and Scleroderma Renal Crisis. Finally, we review the therapeutic landscape, moving from established treatments like ACE inhibitors and nintedanib to emerging frontiers like CAR-T cell therapy and autologous hematopoietic stem cell transplantation.

In this episode, we explore the clinical landscape of Microtia, Atresia, and Hemifacial Microsomia, congenital conditions ranging from the underdevelopment of the external ear to complex craniofacial asymmetry. We examine the spectrum of these anomalies—from the "peanut ear" of Grade III microtia to the syndromic features of Goldenhar syndrome—and discuss leading etiological theories involving vascular disruption and neural crest cell disturbance during embryogenesis. We break down the critical debate between surgical reconstruction options, comparing the durability of autologous rib cartilage grafts (typically performed after age 8) against the earlier intervention potential of synthetic Medpor implants. Finally, we highlight essential hearing management strategies, such as bone-anchored hearing aids (BAHA) and atresiaplasty, while addressing the significant psychosocial impacts—including anxiety and depression—that advocacy groups like Ear Community strive to mitigate.